Fig. 2: Homozygous SMARCA4 mutations in NSCLC. | Nature Communications

Fig. 2: Homozygous SMARCA4 mutations in NSCLC.

From: Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients

Fig. 2

a Co-occurrence of SMARCA4 mutations with common oncogenic drivers in lung cancer patients excluding variants of unknown significance (n = 19,848 patients). b Summary table of odds ratio (OR) and P values using a two-tailed Fisher’s exact test (not adjusted for multiple testing) for patients in a. c Overall survival of patients with SMARCA4 mutations. d Overall survival of patients with SMARCA4 mutations that have received cancer immunotherapy at any time during their treatment. The log-rank test was used to compare the overall survival of groups and resulting P values are unadjusted (c–d).

Back to article page